Navigation Links
iBio, Inc. Submits Plan to Satisfy NYSE Amex Continued Listing Standards

NEWARK, Del., Nov. 30, 2011 /PRNewswire/ -- iBio, Inc. (NYSE AMEX: IBIO) today announced that it has submitted its plan (the "Plan") to satisfy the requirements for continued listing on the NYSE Amex LLC (the "Exchange") to the Exchange's Corporate Compliance Department management (the "Staff") for their review, and that the Company is currently awaiting a response from the Staff in connection therewith.  As previously announced, the Staff indicated that its review of the Company's Form 10-K for the year ended June 30, 2011, indicated that the Company is not in compliance with Section 1003(a)(iv), as more particularly described in the Company's November 7 press release.

Questions received by the Company following its November 7th press release reflected lack of public understanding of the process followed by the Exchange.  Consequently, iBio wishes to provide a brief description of the process the Exchange follows after submission of a Plan.

The Staff will evaluate the Plan, including any supporting documentation, and make a determination as to whether the Company has made a reasonable demonstration of its ability to regain compliance with the continued listing standards within the specified time frame.  If the Staff concludes that the Company has made the necessary demonstration, the Plan will be accepted and the Company will be able to continue its listing during the Plan period.  The Company will be subject to periodic reviews during the Plan period to determine whether it is making progress consistent with the Plan. If the Staff determines that the Company is not making the necessary progress, consistent with the Plan, it may terminate the Plan period and initiate delisting proceedings.

If the Plan is not accepted, or if the Company fails to demonstrate compliance with the applicable listing requirements by the end of the Plan period, the Staff will initiate delisting proceedings. However, the Company may appeal a Staff determination to initiate delisting proceedings to an independent Listing Qualifications Panel of the Exchange Committee on Securities (the "Panel") in accordance with the Exchange's Company Guide. The filing of an appeal would stay any delisting action at least until the Panel renders its decision following a hearing. It generally takes approximately 45 days to hold such a hearing.

About iBio, Inc.

iBio develops and offers product applications of its iBioLaunch™ platform, providing collaborators full support for turn-key implementation of its technology for both proprietary and biosimilar products. The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. The technology has been applied successfully to proteins difficult or impossible to produce with other methods, as well as proteins representative most important classes of biologic pharmaceuticals. Advantages of the iBioLaunch platform over other systems include enablement of rapid development and validation of modular, scalable, and optionally robotic, multi-product manufacturing facilities; production time measured in weeks instead of months or more; product entry that is unconstrained by traditional process patents; and significantly lower capital and operating costs for comparable production. Further information is available at:

Forward-Looking Statements

Statements included in this news release related to iBio, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the Company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects. Further information on potential risk factors that could affect the Company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission.


Robert Erwin, President 
iBio, Inc. 

Douglas Beck, CFO
iBio, Inc.

SOURCE iBio, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. iBio, Inc. Receives Notice from NYSE Amex Staff that Company Currently is Below Certain Continued Listing Standards
2. Roche Submits Acute Hepatitis B Test to FDA for Premarket Approval
3. Amgen Submits Application to Expand Indication for XGEVA® (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the Bone
4. MAP Pharmaceuticals Submits New Drug Application to FDA for LEVADEX® Orally Inhaled Migraine Drug
5. Dendreon Submits Post-Approval Supplement to the PROVENGE Biologics License Application for New Jersey Manufacturing Facility
6. Advanced Life Sciences Submits Full Proposal to NIAID for Development of Intravenous Formulation of Restanza as a Biodefense Countermeasure
7. 3SBio Inc. Submits Application for NuPIAO Phase I Clinical Trial
8. PharmAthene Submits White Paper to BARDA for Advanced Development Funding for SparVax(TM) - Novel Recombinant Protective Antigen Anthrax Vaccine
9. Osteotech Submits 510(k) Application to FDA for Clearance of its Duratech(TM) BioRegeneration Matrix
10. Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease
11. Collaboration of Indianas Health Information Exchanges, State Organizations Submits Application for Health Information Technology Stimulus Funding
Post Your Comments:
(Date:10/10/2015)... Am 8. Oktober hat die Kongressabgeordnete ... Kalifornien) ihre Würdigung der International Plasma Awareness Week ... des Kongresses eintragen lassen. Die IPAW wird von ... und ihren Mitgliedsunternehmen unterstützt. Ihre Ziele bestehen in: ... Plasmaspenden weltweit , Würdigung des Beitrages von ...
(Date:10/9/2015)... , Oct. 9, 2015 On October ... the Congressional Record her statement recognizing the third annual ... 11-17. IPAW is sponsored by the Plasma Protein ... is designed to:   , Raise global awareness ... plasma donors in saving and improving lives , ...
(Date:10/9/2015)... , Oct. 9, 2015 Governor ... clinical stage biopharmaceutical company focused on developing T-cell receptor ... high-paying jobs with a new expansion project. ... news for the commonwealth as 110 new, high-paying jobs ... Tom Wolf . "My budget proposal includes sustained funding ...
(Date:10/9/2015)... and ROCKVILLE, Md. , Oct. ... privately-held biotechnology company developing next generation vaccines based ... has entered into an exclusive worldwide licensing agreement ... the treatment or prevention of any and all ... agreement, Immunomic Therapeutics will receive an upfront payment ...
Breaking Biology Technology:
... , , , ... adolescence today and I see our company providing the technological platform ... Edward Pulwer, upon accepting the position of President/CEO from the Board ... been in business for over 30 years and maintains the largest ...
... ... efficacy endpoints , ... San Diego, CA (PRWEB) July 27, 2009 -- Histogen, Inc., a regenerative medicine company ... the results of the Company,s preliminary clinical trial of Histogen,s HSC human hair regrowth ...
... Graphene is nature,s thinnest elastic material and displays ... planar geometry, high current-carrying capacity and thermal conductivity ... through ultra-small devices and components for semiconductor circuits ... features is ripples, similar to those seen on ...
Cached Biology Technology:
(Date:10/9/2015)... ) ... "Samsung Galaxy S6 Fingerprint Sensor - Reverse ... --> ) has announced ... S6 Fingerprint Sensor - Reverse Costing Analysis" ... Research and Markets ( ) ...
(Date:10/8/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ), ... today that it will report financial results for ... October 22, 2015, after the close of market. ... for analysts and investors at 2:00 p.m. PT ... forward-looking information. ). A ...
(Date:10/8/2015)... , 8. Oktober 2015 Die ... tätiges Unternehmen des Bereiches Tracking, hat heute ... der Gefängnisbehörde Virginias (Department of Corrections – ... Überwachungsdienste für alle Strafen geliefert werden, die ... , Präsident für den Amerikanischen Kontinent der ...
Breaking Biology News(10 mins):
... of America (ESA) will present eight societal awards recognizing outstanding ... Oregon. The meeting, which will be held from August 5 ... around the globe to share their research and ideas. ... Washington, Seattle , This award is given to a senior ...
... Membrane technology is increasingly playing an essential role in ... recent advancements of membrane research, development and applications related ... & purifications, energy issues, the environment, special needs, etc. ... and thoughts, and discussions for the global membrane community. ...
... , WEST LAFAYETTE, Ind. - Scientists could take greater ... of advanced techniques used to understand the mechanisms that ... former Purdue University researchers say. In a perspective ... Purdue assistant professor of genetics, and Ivan Baxter, a ...
Cached Biology News:
... V, is used for agitation and mixing applications ... and destaining of gels and blots, and Southern ... rpm) and can handle a maximum load of ... 29 x 21 cm platforms covered with nonslip ...
... (3-ethylbenzthiazoline-6-sulfonic Acid) Clear to very pale ... H 2 O 2 in a citrate ... that is soluble, safe, convenient and has good ... intense blue-green color that can be measured at ...
Biology Products: